Q4 2016
Released Mar 6, 2017, after the close
10-K filed Mar 6, 2017, 65 days after period end · 0001144204-17-012930
Q4 2016 · 10-K
Revenue—
Net Income-$2.97M-$2.97M N/M vs Q4 2015N/M vs Q3 2016
EPS Diluted-$0.16-$0.16 N/M vs Q4 2015N/M vs Q3 2016
Operating Income-$3,015,090N/M
Operating Cash Flowderived-$2,547,068N/M
Free Cash Flowderived-$2,547,068N/M
What the release said
The release
Same quarter
| Metric | Q4 2016 | Q4 2015 | Q4 2014dderived from reported figures | Q4 2013dderived from reported figures |
|---|---|---|---|---|
| Net Income | -$2.97M | -$4.63M | -$4.04M | -$4.39M |
| EPS Diluted | -$0.16 | -$0.25 | — | — |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Lipocine Inc. · CIK 1535955 · Engraved from SEC EDGAR